Natixis Advisors L.P. Has $154.42 Million Holdings in AbbVie Inc. (NYSE:ABBV)

Natixis Advisors L.P. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 10.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 996,425 shares of the company’s stock after purchasing an additional 91,525 shares during the period. Natixis Advisors L.P.’s holdings in AbbVie were worth $154,415,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. DiNuzzo Private Wealth Inc. bought a new stake in shares of AbbVie in the fourth quarter valued at $44,000. Blue Bell Private Wealth Management LLC increased its stake in shares of AbbVie by 39.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 286 shares of the company’s stock worth $43,000 after purchasing an additional 81 shares in the last quarter. Horrell Capital Management Inc. purchased a new position in AbbVie during the third quarter valued at approximately $45,000. Bourgeon Capital Management LLC increased its holdings in AbbVie by 240.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 340 shares of the company’s stock valued at $53,000 after purchasing an additional 240 shares during the period. Finally, Naples Money Management LLC bought a new stake in AbbVie in the fourth quarter valued at $53,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.4 %

ABBV traded down $2.25 on Thursday, reaching $159.47. 2,943,324 shares of the company traded hands, compared to its average volume of 5,624,253. The company has a market cap of $282.37 billion, a P/E ratio of 47.33, a price-to-earnings-growth ratio of 2.04 and a beta of 0.61. The company has a quick ratio of 0.76, a current ratio of 0.87 and a debt-to-equity ratio of 5.02. AbbVie Inc. has a one year low of $130.96 and a one year high of $182.89. The firm has a fifty day simple moving average of $173.74 and a two-hundred day simple moving average of $161.10.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, April 26th. The company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.26 by $0.05. The firm had revenue of $12.31 billion during the quarter, compared to the consensus estimate of $11.93 billion. AbbVie had a net margin of 11.02% and a return on equity of 165.18%. The company’s revenue was up .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share. As a group, equities research analysts expect that AbbVie Inc. will post 11.3 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a dividend of $1.55 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.89%. AbbVie’s payout ratio is currently 183.98%.

Insider Activity at AbbVie

In other news, EVP Jeffrey Ryan Stewart sold 58,949 shares of AbbVie stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $178.79, for a total value of $10,539,491.71. Following the sale, the executive vice president now owns 60,941 shares in the company, valued at $10,895,641.39. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $173.71, for a total value of $9,184,047.70. Following the completion of the sale, the executive vice president now owns 243,944 shares of the company’s stock, valued at approximately $42,375,512.24. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Ryan Stewart sold 58,949 shares of AbbVie stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $178.79, for a total transaction of $10,539,491.71. Following the completion of the sale, the executive vice president now owns 60,941 shares of the company’s stock, valued at approximately $10,895,641.39. The disclosure for this sale can be found here. Insiders sold a total of 383,324 shares of company stock worth $67,780,003 in the last three months. Company insiders own 0.25% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Guggenheim boosted their price objective on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Raymond James boosted their price objective on shares of AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. BMO Capital Markets reduced their target price on AbbVie from $195.00 to $180.00 and set an “outperform” rating for the company in a report on Monday. Truist Financial upped their price target on AbbVie from $180.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 6th. Finally, William Blair upgraded AbbVie from a “market perform” rating to an “outperform” rating in a research report on Monday, January 29th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $174.31.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.